1 EQ-5D, HUI and SF-36 Of the shelf instruments…..

Slides:



Advertisements
Similar presentations
Comparing different treatments How can we decide?.
Advertisements

Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
1 Could there be a single European EQ tariff? Jan J.V. Busschbach, Ph.D. Former address: –iMTA, Erasmus university Present address: –Medical Psychology.
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
SFU SIMON FRASER UNIVERSITY FACULTY OF HEALTH SCIENCES The (Inevitable and Acceptable) Consequences of Using Generic Patient- Reported Outcomes in Technology.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
Big Q and Little Q revisited Christopher McCabe PhD Capital Health Endowed Research Chair in Emergency Medicine Research.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Prof. dr. Jan van Busschbach Department of Medical Psychology & Psychotherapy Erasmus MC.
Using a discrete choice experiment with duration to estimate values for health states on the QALY scale Nick Bansback Assistant Professor School of Population.
Utility Assessment HINF Medical Methodologies Session 4.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
Health Economics II –2010 Health Economic Evaluations Part III Lecture 2 Cost-effectiveness analysis QALYs and cost-utility analysis Nils-Olov Stålhammar.
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
MAPPING THE DIABETES HEALTH PROFILE (DHP-18) ONTO THE EQ-5D AND SF-6D GENERIC PREFERENCE BASED MEASURES OF HEALTH Brendan Mulhern 1, Keith Meadows 2, Donna.
Introduction to Effectiveness, Patient Preferences and Utilities Patsi Sinnott, PT, PhD, MPH HERC Economics Course May 6, 2009.
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
Measuring the “Q” in QALYs for cost- effectiveness analysis: the EuroQol Group’s approach Valuing health outcomes for healthcare decision making using.
Overview of the EQ-5D Purpose and origins of the descriptive system.
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
Is healthcare any good for patients? Measuring health outcomes using EQ-5D Professor Paul Kind Principal Investigator Outcomes Research Group Centre for.
Presentations: Quantifying the impact of adverse events on HRQOL early after implant Patient selection and estimation of prognosis using health status.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 11: Cost-utility analysis – Part 4.
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
New and ongoing areas of research In the EuroQol Group.
Health State Unable to perform some tasks at home and/or at work Able to perform all self care activities (eating, bathing, dressing) albeit with some.
EQ-5D AND QUALITY OF LIFE OF OSTEOPOROSIS AT-RISK PATIENTS IN A SWEDISH OSTEOPOROSIS PATIENT REGISTRY Arun Krishna 1, Dan Mellström 2, Zhiyi Li 3, Chun-Po.
University of Minnesota Medical Technology Evaluation and Market Research Department of Healthcare Management Course: MILI/PUBH 6589 Spring Semester, 2013.
Quality of Life in People with and at Risk for Type 2 Diabetes: Findings from the Study to Help Improve Early Evaluation and Management of Risk Factors.
1 Patient values or values from the general public.
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
The experience of Denmark with Summary Measures of Population Health 7 th Meeting of the Task Force on Health Expectancies Luxembourg, 2 December 2008.
Patsi Sinnott, PT, PhD, MPH HERC Economics Course April 7, 2010 Introduction to Effectiveness, Patient Preferences and Utilities.
Governance and Public Policy: a NICE example John Brazier Professor of Health Economics, ScHARR, University of Sheffield, UK With thanks to Matt Stevenson.
Overview of Health-Related Quality of Life Measures May 22, 2014 (1:00 – 2:00 PDT) Kaiser Methods Webinar Series 1 Ron D.Hays, Ph.D.
Health-Related Quality of Life Preference Measures for Vision Studies Ron D. Hays, Ph.D. UCLA GIM & HSR June 10, 2009 (2:30-4:00 pm) Irvine, CA.
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
Using a Discrete Choice Experiment to Value the EQ-5D-5L in Canada Nick Bansback Assistant Professor School of Population and Public Health, University.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
Applying Expectancy-value Model to understand Health Preference An Exploratory Study Xu-Hao Zhang Department of Pharmacy National University of Singapore.
Hermann P. G. Schneider, Alastair H. MacLennan and David Feeny
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
Overlap between Subjective Well-being and Health-related Quality of Life. 3 Ron D. Hays, Ph.D. (Alina Palimaru) November 18, 2015 (11:30-12:00 noon) Geriatric.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Heidi Livingstone, Senior Public Involvement Adviser.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
1 VAS, SG, TTO and PTO An Interactive Introduction.
Canadian TTO Valuations of the EQ-5D-5L: East versus West Differences
Table 1. Characteristics of generic HRQOL assessments in adult physical activity research Peter D. Hart et al. Systematic Review of Health-Related Quality.
1 Utilization of Quality of Life Research in Decision-Making and Policy  Prof. Dr. Jan J.V. Busschbach  Erasmus MC, Rotterdam, The Netherlands  Section.
The burden of disease in patients with personality disorder indicated for psychotherapy: Arguments for necessity of care Djøra Soeteman, MSc
M. Dakoutrou, V. Gerovasili, G. Sidiras, I. Patsaki, A. Kouvarakos, S
Patient Baseline Assessment
Prof. Dr. Jan J.V. Busschbach
The valuation of disease-specific questionnaires for QALY analysis
Is healthcare any good for patients
Impact of Mode and Order of Administration on Generic HRQOL Scores
Measuring outcomes Emma Frew October 2012.
How to Measure Quality of Life
Presentation transcript:

1 EQ-5D, HUI and SF-36 Of the shelf instruments….

2 Direct valuation

3 …or use validated questionnaires MOBILITY  I have no problems in walking about  I have some problems in walking about  I am confined to bed SELF-CARE  I have no problems with self-care  I have some problems washing or dressing myself  I am unable to wash or dress myself USUAL ACTIVITIES (e.g. work, study, housework family or leisure activities)  I have no problems with performing my usual activities  I have some problems with performing my usual activities  I am unable to perform my usual activities PAIN/DISCOMFORT  I have no pain or discomfort  I have moderate pain or discomfort  I have extreme pain or discomfort ANXIETY/DEPRESSION  I am not anxious or depressed  I am moderately anxious or depressed  I am extremely anxious or depressed

4 Validated questionnaires

5 The Rosser & Kind Index

6 The Rosser & Kind index  One of the oldest valuation  1978: Magnitude estimation  Magnitude estimation  PTO  N = 70: Doctors, nurses, patients and general public  1982: Transformation to “utilities”  1985: High impact article  Williams A. For Debate... Economics of Coronary Artery Bypass Grafting. British Medical Journal 291: ,  Survey at the celebration of 25 years of health economics: chosen most influential article on health economics

7 More health states  Criticism on the Rosser & Kind index  Sensitivity (only 30 health states)  The unclear meaning of “distress”  The compression of states in the high values  The involvement of medical personnel  New initiatives  Higher sensitivity (more then 30 states)  More and better defined dimensions  Other valuation techniques Standard Gamble, Time Trade-Off  Values of the general public

8 Validated questionnaires

9 No longer value all states  Impossible to value all health states  If one uses more than 30 health states  Estimated the value of the other health states with statistical techniques  Statistically inferred strategies Regression techniques EuroQol, Quality of Well-Being Scale (QWB)  Explicitly decomposed methods Multi Attribute Utility Theory (MAUT) Health Utility Index (HUI)

10 Statistically inferred strategies  Value a sample of states empirically  Extrapolation  Statistical methods, like linear regression  = 1.00  =.70  = ?

11 Statistically inferred strategies  EuroQol  EQ-5D: 5 dimensions of health  245 health states  Quality of Well-Being scale (QWB)  4 dimensions of health  2200 health states plus 22 additional symptoms  SF-36  SF-6D: 6 dimensions of health  health states

12 Explicitly Decomposed Methods  Value dimensions separately  Between the dimensions  What is the relative value of: Mobility…... 20% Mood…….. 15% Self care.… 24%.  Value the levels  Within the dimensions  What is the relative value of Some problems with walking…… 80% Much problems with walking…... 50% Unable to walk…………………….10%

13 Explicitly Decomposed Methods  Combine values of dimensions and levels with specific assumptions  Multi Attribute Utility Theory (MAUT) Mutual utility independence Structural independence

14 Explicitly Decomposed Methods  Health Utilities Index (Mark 2 & 3)  Torrance at McMaster  8 dimensions  Mark 2: health states  Mark 3: health states  The 15-D  Sintonen H.  15 dimensions  3,052,000,000 health states (3 billion)

Exercise EQ-5D: X X X X X

Scoring EQ-5D state

Converting SF-36 into SF-6D 17 X X X X

Scoring the SF-6D 18

19 More health states, higher sensitivity ? (1)  EuroQol criticised for low sensitivity  Low number of dimensions Development of EQ-5D plus cognitive dimension  Low number of levels (3) Gab between best and in-between level

20 More health states, higher sensitivity ? (2)  Little published evidence  Sensitivity EQ-5D < SF-36 Compared as profile, not as utility measure  Sensitivity EQ-5D  HUI  Sensitivity  the number of health states  How well maps the classification system the illness?  How valid is the modelling?  How valid is the valuation?

21 More health states, more assumptions  General public values at the most 50 states  The ratios empirical (50) versus extrapolated  Rosser & Kind1:1  EuroQol1:5  QWB1:44  SF-361:180  HUI (Mark III)1:19,400  15D1:610,000,000  What is the critical ratio for a valid validation?

22 SF-36 as utility instrument  Transformed into SF6D  SG  N = 610  Inconsistencies in model  health states  regression technique stressed to the edge  Floor effect in SF6D

23 Conflicting evidence sensitivity SF-36 Liver transplantation, Longworth et al., 2001

24 EQ-5D  Strong punts  Very sensitive in the low  Measures subjective burden (inside the skin)  Low administrative burden  Many translations  Cheap  Most used QALY questionnaire  Most international validations  Weak points  Only there levels per dimensions  Insensitive in the high regions

25 HUI  Strong punts  Sensitive  Measures objective burden (outside the skin)  Well developed proxy versions  Well developed child versions  Weak points  Expensive

26 SF-6D  Strong punts  Probably sensitive in the high regions  Often already include in trials (SF-36)  Cheap  Many translations  Weak points  Insensitive in the low regions  Only one validation study  Changed Standard Gamble Upwards shift of values

27 Conclusions  More states  better sensitivity  The three leading questionnaires  have different strong and weak points